COUR Pharmaceutical Development Company, Inc.
CNP-103
Type 1 Diabetes Mellitus
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for CNP-103 in Type 1 Diabetes Mellitus are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06783309: Phase 2 trial, sponsor COUR Pharmaceutical Development Company, Inc., drug CNP-103. Primary completion date 2026-12 (estimated).”